{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:38:00Z","timestamp":1792715880843,"version":"4.5.0"},"reference-count":187,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100017001","name":"Li Ka Shing Institute of Virology, University of Alberta","doi-asserted-by":"publisher","award":["RES0073963"],"award-info":[{"award-number":["RES0073963"]}],"id":[{"id":"10.13039\/501100017001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["481194"],"award-info":[{"award-number":["481194"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.drudis.2026.104822","type":"journal-article","created":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:08:52Z","timestamp":1791216532000},"page":"104822","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Overview of screening assays used to evaluate PROTACs for cancer treatment"],"prefix":"10.1016","volume":"31","author":[{"given":"Raghd","family":"Obidat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jazmin","family":"Reyes-Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"AlRawashdeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Loredo-Calderon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4535-1835","authenticated-orcid":false,"given":"Carlos A.","family":"Vel\u00e1zquez-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2026.104822_b0005","doi-asserted-by":"crossref","first-page":"17098","DOI":"10.1021\/acs.jmedchem.1c01069","article-title":"Targeting of the FOXM1 oncoprotein by E3 ligase-assisted degradation","volume":"64","author":"Luo","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104822_b0010","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"Bekes","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2026.104822_b0015","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s43556-022-00112-0","article-title":"An overview of PROTACs: a promising drug discovery paradigm","volume":"3","author":"Liu","year":"2022","journal-title":"Mol Biomed"},{"key":"10.1016\/j.drudis.2026.104822_b0020","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.tips.2020.02.006","article-title":"Critical assessment of targeted protein degradation as a research tool and pharmacological modality","volume":"41","author":"Kostic","year":"2020","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.drudis.2026.104822_b0025","doi-asserted-by":"crossref","first-page":"8554","DOI":"10.1073\/pnas.141230798","article-title":"PROTACs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation","volume":"98","author":"Sakamoto","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.drudis.2026.104822_b0030","doi-asserted-by":"crossref","first-page":"5214","DOI":"10.1039\/D2CS00193D","article-title":"PROTACs: past, present and future","volume":"51","author":"Li","year":"2022","journal-title":"Chem Soc Rev"},{"key":"10.1016\/j.drudis.2026.104822_b0035","article-title":"A beginner\u2019s guide to current synthetic linker strategies towards VHL-recruiting PROTACs","volume":"88\u201389","author":"Zografou-Barredo","year":"2023","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.drudis.2026.104822_b0040","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1053\/j.seminoncol.2016.06.001","article-title":"Critical parameters in targeted drug development: the pharmacological audit trail","volume":"43","author":"Banerji","year":"2016","journal-title":"Semin Oncol"},{"key":"10.1016\/j.drudis.2026.104822_b0045","doi-asserted-by":"crossref","first-page":"14129","DOI":"10.1021\/acs.jmedchem.5c01818","article-title":"NDA submission of vepdegestrant (ARV-471) to U.S. FDA: the beginning of a new era of PROTAC degraders","volume":"68","author":"Ma","year":"2025","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104822_b0050","unstructured":"U.S. Food and Drug Administration. FDA approves vepdegestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer. Accessed 17 July 2026. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-vepdegestrant-er-positive-her2-negative-esr1-mutated-advanced-or-metastatic-breast."},{"key":"10.1016\/j.drudis.2026.104822_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2025.117297","article-title":"Molecular glues and PROTACs in targeted protein degradation: mechanisms, advances, and therapeutic potential","volume":"242","author":"Eladl","year":"2025","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.drudis.2026.104822_b0060","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1016\/j.apsb.2026.02.020","article-title":"Molecular glue degraders: rational design, specificity engineering, and advanced delivery","volume":"16","author":"Ma","year":"2026","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.drudis.2026.104822_b0065","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.4155\/fmc-2020-0073","article-title":"Assays and technologies for developing proteolysis targeting chimera degraders","volume":"12","author":"Liu","year":"2020","journal-title":"Future Med Chem"},{"key":"10.1016\/j.drudis.2026.104822_b0070","doi-asserted-by":"crossref","first-page":"7124","DOI":"10.3390\/ijms25137124","article-title":"Binding affinity determination in drug design: insights from lock and key, induced fit, conformational selection, and inhibitor trapping models","volume":"25","author":"Spassov","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2026.104822_b0075","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3390\/ijms17020144","article-title":"Insights into protein-ligand interactions: mechanisms, models, and methods","volume":"17","author":"Du","year":"2016","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2026.104822_b0080","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.chembiol.2023.06.019","article-title":"DELs enable the development of BRET probes for target engagement studies in cells","volume":"30","author":"Teske","year":"2023","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.drudis.2026.104822_b0085","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1007\/s00044-019-02485-4","article-title":"Design, synthesis, and biological evaluation of small molecule PROTACs for potential anticancer effects","volume":"29","author":"Da","year":"2019","journal-title":"Med Chem Res"},{"key":"10.1016\/j.drudis.2026.104822_b0090","doi-asserted-by":"crossref","first-page":"6665","DOI":"10.7150\/thno.75444","article-title":"Design of stapled peptide-based PROTACs for MDM2\/MDMX atypical degradation and tumor suppression","volume":"12","author":"Chen","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.drudis.2026.104822_b0095","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1021\/acs.jmedchem.3c01493","article-title":"Degradation of polo-like kinase 1 by the novel poly-arginine N-degron pathway PROTAC regulates tumor growth in nonsmall cell lung cancer","volume":"67","author":"Gunasekaran","year":"2024","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104822_b0100","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/j.apsb.2020.11.022","article-title":"Homo-PROTAC mediated suicide of MDM2 to treat non-small cell lung cancer","volume":"11","author":"He","year":"2021","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.drudis.2026.104822_b0105","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1021\/acs.jmedchem.8b00909","article-title":"Discovery of MD-224 as a first-in-class, highly potent, and efficacious proteolysis targeting chimera murine double minute 2 degrader capable of achieving complete and durable tumor regression","volume":"62","author":"Li","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104822_b0110","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2023.1219883","article-title":"Development of the first geldanamycin-based HSP90 degraders","volume":"11","author":"Wurnig","year":"2023","journal-title":"Front Chem"},{"key":"10.1016\/j.drudis.2026.104822_b0115","doi-asserted-by":"crossref","first-page":"4197","DOI":"10.1021\/acs.jmedchem.3c00075","article-title":"Discovery of a potent, cooperative, and selective SOS1 PROTAC ZZ151 with in vivo antitumor efficacy in KRAS-mutant cancers","volume":"66","author":"Zhou","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104822_b0120","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.chembiol.2017.09.010","article-title":"Lessons in PROTAC design from selective degradation with a promiscuous warhead","volume":"25","author":"Bondeson","year":"2018","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.drudis.2026.104822_b0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2025.104376","article-title":"PROTAC 2.0: expanding the frontiers of targeted protein degradation","volume":"30","author":"Cornu","year":"2025","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.drudis.2026.104822_b0130","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1517\/17460441.2011.537322","article-title":"Fluorescence polarization assays in small molecule screening","volume":"6","author":"Lea","year":"2011","journal-title":"Expert Opin Drug Discov"},{"key":"10.1016\/j.drudis.2026.104822_b0135","doi-asserted-by":"crossref","first-page":"167","DOI":"10.2174\/138620703106298347","article-title":"Fluorescence polarization: past, present and future","volume":"6","author":"Jameson","year":"2003","journal-title":"Comb Chem High Throughput Screen"},{"key":"10.1016\/j.drudis.2026.104822_b0140","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1006\/meth.2000.1038","article-title":"Fluorescence polarization immunoassay: detection of antibody to Brucella abortus","volume":"22","author":"Nielsen","year":"2000","journal-title":"Methods"},{"key":"10.1016\/j.drudis.2026.104822_b0145","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/s41589-018-0055-y","article-title":"Plasticity in binding confers selectivity in ligand-induced protein degradation","volume":"14","author":"Nowak","year":"2018","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.drudis.2026.104822_b0150","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/nprot.2011.305","article-title":"Analysis of protein-ligand interactions by fluorescence polarization","volume":"6","author":"Rossi","year":"2011","journal-title":"Nat Protoc"},{"key":"10.1016\/j.drudis.2026.104822_b0155","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S1367-5931(00)00251-9","article-title":"Surface plasmon resonance: towards an understanding of the mechanisms of biological molecular recognition","volume":"5","author":"McDonnell","year":"2001","journal-title":"Curr Opin Chem Biol"},{"key":"10.1016\/j.drudis.2026.104822_b0160","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1021\/acsmedchemlett.4c00065","article-title":"Discovery of the first potent DYRK2 proteolysis targeting chimera degraders","volume":"15","author":"Chen","year":"2024","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.drudis.2026.104822_b0165","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ebiom.2019.10.013","article-title":"A novel strategy to block mitotic progression for targeted therapy","volume":"49","author":"Chi","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.drudis.2026.104822_b0170","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1158\/0008-5472.CAN-24-1093","article-title":"Targeted degradation of SOS1 exhibits potent anticancer activity and overcomes resistance in KRAS-mutant tumors and BCR-ABL-positive leukemia","volume":"85","author":"Luo","year":"2025","journal-title":"Cancer Res"},{"key":"10.1016\/j.drudis.2026.104822_b0175","doi-asserted-by":"crossref","first-page":"3923","DOI":"10.1021\/acs.jmedchem.1c01774","article-title":"Discovery of the first-in-class agonist-based SOS1 PROTACs effective in human cancer cells harboring various KRAS mutations","volume":"65","author":"Zhou","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104822_b0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114462","article-title":"Discovery of precision targeting EZH2 degraders for triple-negative breast cancer","volume":"238","author":"Wang","year":"2022","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.drudis.2026.104822_b0185","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1021\/ac802276x","article-title":"Plasmonic nanoholes in a multichannel microarray format for parallel kinetic assays and differential sensing","volume":"81","author":"Im","year":"2009","journal-title":"Anal Chem"},{"key":"10.1016\/j.drudis.2026.104822_b0190","first-page":"161","article-title":"Real-time and label-free bio-sensing of molecular interactions by surface plasmon resonance: a laboratory medicine perspective","volume":"33","author":"Helmerhorst","year":"2012","journal-title":"Clin Biochem Rev"},{"key":"10.1016\/j.drudis.2026.104822_b0195","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/cyto.a.22851","article-title":"Overcoming limitations of FRET measurements","volume":"89","author":"Leavesley","year":"2016","journal-title":"Cytometry A"},{"key":"10.1016\/j.drudis.2026.104822_b0200","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1177\/1087057111422102","article-title":"A substrate-independent TR-FRET histone deacetylase inhibitor assay","volume":"16","author":"Marks","year":"2011","journal-title":"J Biomol Screen"},{"key":"10.1016\/j.drudis.2026.104822_b0205","doi-asserted-by":"crossref","first-page":"18549","DOI":"10.1021\/acs.jmedchem.4c01926","article-title":"First-in-class small molecule degrader of pregnane X receptor enhances chemotherapy efficacy","volume":"67","author":"Huber","year":"2024","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104822_b0210","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/jmr.1025","article-title":"Survey of the year 2008: applications of isothermal titration calorimetry","volume":"23","author":"Falconer","year":"2010","journal-title":"J Mol Recognit"},{"key":"10.1016\/j.drudis.2026.104822_b0215","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/jmr.803","article-title":"Survey of the year 2005: literature on applications of isothermal titration calorimetry","volume":"20","author":"Ababou","year":"2007","journal-title":"J Mol Recognit"},{"key":"10.1016\/j.drudis.2026.104822_b0220","first-page":"2796","article-title":"Isothermal titration calorimetry for measuring macromolecule-ligand affinity","author":"Duff","year":"2011","journal-title":"J Vis Exp"},{"key":"10.1016\/j.drudis.2026.104822_b0225","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/bs.mie.2020.12.017","article-title":"Biophysical approaches to study actinoporin-lipid interactions","volume":"649","author":"Palacios-Ortega","year":"2021","journal-title":"Methods Enzymol"},{"key":"10.1016\/j.drudis.2026.104822_b0230","doi-asserted-by":"crossref","first-page":"9815","DOI":"10.1021\/jacs.3c01852","article-title":"Small-molecule ferritin degrader as a pyroptosis inducer","volume":"145","author":"Chen","year":"2023","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.drudis.2026.104822_b0235","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.3390\/pharmaceutics17081027","article-title":"N-degron-based PROTAC targeting PLK1: a potential therapeutic strategy for cervical cancer","volume":"17","author":"Gunasekaran","year":"2025","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.drudis.2026.104822_b0240","doi-asserted-by":"crossref","first-page":"12331","DOI":"10.1021\/acs.jmedchem.4c03115","article-title":"Target engagement assays in early drug discovery","volume":"68","author":"John-Campbell","year":"2025","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104822_b0245","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1021\/acschembio.1c00760","article-title":"High-throughput cellular thermal shift assay using acoustic transfer of protein lysates","volume":"17","author":"Owens","year":"2022","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.drudis.2026.104822_b0250","doi-asserted-by":"crossref","first-page":"3940","DOI":"10.3390\/ijms26093940","article-title":"Applications of the cellular thermal shift assay to drug discovery in natural products: a review","volume":"26","author":"Song","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2026.104822_b0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.slasd.2024.100172","article-title":"A robust CETSA data analysis automation workflow for routine screening","volume":"29","author":"Florez Weidinger","year":"2024","journal-title":"SLAS Discov"},{"key":"10.1016\/j.drudis.2026.104822_b0260","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1021\/acsmedchemlett.1c00276","article-title":"Rapid evaluation of small molecule cellular target engagement with a luminescent thermal shift assay","volume":"12","author":"Mortison","year":"2021","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.drudis.2026.104822_b0265","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1016\/j.apsb.2021.12.017","article-title":"NAMPT-targeting PROTAC promotes antitumor immunity via suppressing myeloid-derived suppressor cell expansion","volume":"12","author":"Wu","year":"2022","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.drudis.2026.104822_b0270","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1021\/acs.jmedchem.0c02234","article-title":"Design and synthesis of EZH2-based PROTACs to degrade the PRC2 complex for targeting the noncatalytic activity of EZH2","volume":"64","author":"Liu","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104822_b0275","doi-asserted-by":"crossref","first-page":"5737","DOI":"10.1007\/s11030-025-11460-8","article-title":"A novel matrine derivative B10 exerts its anti-liver cancer activity in vitro and in vivo via targeting FGFR3\/PI3K\/AKT signaling pathway","volume":"30","author":"Wang","year":"2026","journal-title":"Mol Divers"},{"key":"10.1016\/j.drudis.2026.104822_b0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108626","article-title":"A novel designed fully peptide-based PROTAC, FPP29, demonstrates its potent cytotoxic effects to liver cancer HCCLM3 cells by targeting FOXM1","volume":"163","author":"Jia","year":"2025","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.drudis.2026.104822_b0285","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ab.2013.04.028","article-title":"Development of an AlphaScreen assay for discovery of inhibitors of low-affinity glycan-lectin interactions","volume":"439","author":"Yegorova","year":"2013","journal-title":"Anal Biochem"},{"key":"10.1016\/j.drudis.2026.104822_b0290","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s13045-022-01258-8","article-title":"A proteolysis-targeting chimera molecule selectively degrades ENL and inhibits malignant gene expression and tumor growth","volume":"15","author":"Li","year":"2022","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.drudis.2026.104822_b0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2019.115228","article-title":"Discovery of a new class of PROTAC BRD4 degraders based on a dihydroquinazolinone derivative and lenalidomide\/pomalidomide","volume":"28","author":"Zhang","year":"2020","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.drudis.2026.104822_b0300","article-title":"Design, synthesis, and evaluation of BCL-2 targeting PROTACs","volume":"30","author":"Bricelj","year":"2024","journal-title":"Chemistry"},{"key":"10.1016\/j.drudis.2026.104822_b0305","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/9780470559277.ch110180","article-title":"Target identification using drug affinity responsive target stability (DARTS)","volume":"3","author":"Lomenick","year":"2011","journal-title":"Curr Protoc Chem Biol"},{"key":"10.1016\/j.drudis.2026.104822_b0310","first-page":"197","article-title":"Novel proteolysis-targeting chimera targeting RAD51 for the treatment of triple-negative breast cancer","volume":"76","author":"Kim","year":"2025","journal-title":"J Physiol Pharmacol"},{"key":"10.1016\/j.drudis.2026.104822_b0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108909","article-title":"Elaboration and profiling of the first OSBP degrader issued from natural Schweinfurthins","volume":"164","author":"Guimard","year":"2025","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.drudis.2026.104822_b0320","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1038\/nprot.2007.321","article-title":"The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability","volume":"2","author":"Niesen","year":"2007","journal-title":"Nat Protoc"},{"key":"10.1016\/j.drudis.2026.104822_b0325","doi-asserted-by":"crossref","first-page":"10165","DOI":"10.1038\/s41467-024-54500-x","article-title":"Crystal structures of DCAF1-PROTAC-WDR5 ternary complexes provide insight into DCAF1 substrate specificity","volume":"15","author":"Mabanglo","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2026.104822_b0330","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/978-1-0716-1665-9_7","article-title":"An in vitro pull-down assay of the E3 ligase:PROTAC:substrate ternary complex to identify effective PROTACs","volume":"2365","author":"Bondeson","year":"2021","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.drudis.2026.104822_b0335","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/978-1-0716-1665-9_5","article-title":"Mechanistic and structural features of PROTAC ternary complexes","volume":"2365","author":"Casement","year":"2021","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.drudis.2026.104822_b0340","doi-asserted-by":"crossref","first-page":"4177","DOI":"10.1038\/s41467-023-39904-5","article-title":"Affinity and cooperativity modulate ternary complex formation to drive targeted protein degradation","volume":"14","author":"Wurz","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2026.104822_b0345","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1021\/acsmedchemlett.1c00543","article-title":"Degradation of protein kinases: ternary complex, cooperativity, and selectivity","volume":"12","author":"Grigglestone","year":"2021","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.drudis.2026.104822_b0350","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/bs.mie.2022.08.055","article-title":"Monitoring PROTAC interactions in biochemical assays using Lumit immunoassays","volume":"681","author":"Crummy","year":"2023","journal-title":"Methods Enzymol"},{"key":"10.1016\/j.drudis.2026.104822_b0355","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbagen.2023.130398","article-title":"Comparative analysis of biophysical methods for monitoring protein proximity induction in the development of small molecule degraders","volume":"1867","author":"Przytulski","year":"2023","journal-title":"Biochim Biophys Acta Gen Subj"},{"key":"10.1016\/j.drudis.2026.104822_b0360","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/108705710200700102","article-title":"A comparison of ALPHAScreen, TR-FRET, and TRF as assay methods for FXR nuclear receptors","volume":"7","author":"Glickman","year":"2002","journal-title":"J Biomol Screen"},{"key":"10.1016\/j.drudis.2026.104822_b0365","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1021\/acsptsci.1c00032","article-title":"General stepwise approach to optimize a TR-FRET assay for characterizing the BRD\/PROTAC\/CRBN ternary complex","volume":"4","author":"Lin","year":"2021","journal-title":"ACS Pharmacol Transl Sci"},{"key":"10.1016\/j.drudis.2026.104822_b0370","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1021\/acschembio.9b00092","article-title":"SPR-measured dissociation kinetics of PROTAC ternary complexes influence target degradation rate","volume":"14","author":"Roy","year":"2019","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.drudis.2026.104822_b0375","doi-asserted-by":"crossref","first-page":"22","DOI":"10.2174\/1875397300903010022","article-title":"HTRF: a technology tailored for drug discovery \u2013 a review of theoretical aspects and recent applications","volume":"3","author":"Degorce","year":"2009","journal-title":"Curr Chem Genomics"},{"key":"10.1016\/j.drudis.2026.104822_b0380","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1177\/2472555218771610","article-title":"Comparing flow cytometry QBeads PlexScreen assays with other immunoassays for determining multiple analytes","volume":"23","author":"Ding","year":"2018","journal-title":"SLAS Discov"},{"key":"10.1016\/j.drudis.2026.104822_b0385","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1186\/s12936-015-0708-1","article-title":"Development of two novel high-throughput assays to quantify ubiquitylated proteins in cell lysates: application to screening of new anti-malarials","volume":"14","author":"Mata-Cantero","year":"2015","journal-title":"Malar J"},{"key":"10.1016\/j.drudis.2026.104822_b0390","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20231519","article-title":"PROTAC-mediated NR4A1 degradation as a novel strategy for cancer immunotherapy","volume":"221","author":"Wang","year":"2024","journal-title":"J Exp Med"},{"key":"10.1016\/j.drudis.2026.104822_b0395","doi-asserted-by":"crossref","DOI":"10.1016\/j.xpro.2024.103080","article-title":"Protocol to test for the formation of ternary protein complexes in vivo or in vitro using a two-step immunoprecipitation approach","volume":"5","author":"Zhang","year":"2024","journal-title":"STAR Protoc"},{"key":"10.1016\/j.drudis.2026.104822_b0400","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.3390\/ph18121867","article-title":"Synthesis and evaluation of AS1411-lenalidomide-targeted degradation chimera in antitumor therapy","volume":"18","author":"Ma","year":"2025","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.drudis.2026.104822_b0405","doi-asserted-by":"crossref","first-page":"e115","DOI":"10.1002\/cpcb.115","article-title":"Proximity ligation assay for detecting protein-protein interactions and protein modifications in cells and tissues in situ","volume":"89","author":"Hegazy","year":"2020","journal-title":"Curr Protoc Cell Biol"},{"key":"10.1016\/j.drudis.2026.104822_b0410","doi-asserted-by":"crossref","first-page":"e58","DOI":"10.1002\/cpim.58","article-title":"Proximity ligation assay (PLA)","volume":"123","author":"Alam","year":"2018","journal-title":"Curr Protoc Immunol"},{"key":"10.1016\/j.drudis.2026.104822_b0415","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/978-1-0716-1665-9_8","article-title":"Kinetic detection of E3:PROTAC:target ternary complexes using NanoBRET technology in live cells","volume":"2365","author":"Mahan","year":"2021","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.drudis.2026.104822_b0420","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1021\/acschembio.5b00143","article-title":"NanoBRET\u2014a novel BRET platform for the analysis of protein-protein interactions","volume":"10","author":"Machleidt","year":"2015","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.drudis.2026.104822_b0425","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.chembiol.2023.06.002","article-title":"Tracking the PROTAC degradation pathway in living cells highlights the importance of ternary complex measurement for PROTAC optimization","volume":"30","author":"Schwalm","year":"2023","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.drudis.2026.104822_b0430","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1038\/s41591-019-0668-z","article-title":"A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity","volume":"25","author":"Khan","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.drudis.2026.104822_b0435","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1039\/D5MD00119F","article-title":"Discovery of PZ671, a highly potent and in vivo active CRBN-recruiting Bcl-xL degrader","volume":"16","author":"Zhang","year":"2025","journal-title":"RSC Med Chem"},{"key":"10.1016\/j.drudis.2026.104822_b0440","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/nchembio.2329","article-title":"Structural basis of PROTAC cooperative recognition for selective protein degradation","volume":"13","author":"Gadd","year":"2017","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.drudis.2026.104822_b0445","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1083\/jcb.201902074","article-title":"Post-translational regulation of ubiquitin signaling","volume":"218","author":"Song","year":"2019","journal-title":"J Cell Biol"},{"key":"10.1016\/j.drudis.2026.104822_b0450","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1038\/embor.2009.192","article-title":"Efficient protection and isolation of ubiquitylated proteins using tandem ubiquitin-binding entities","volume":"10","author":"Hjerpe","year":"2009","journal-title":"EMBO Rep"},{"key":"10.1016\/j.drudis.2026.104822_b0455","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.bbrc.2022.08.048","article-title":"Accelerating PROTAC drug discovery: establishing a relationship between ubiquitination and target protein degradation","volume":"628","author":"Gross","year":"2022","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.drudis.2026.104822_b0460","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/15384047.2022.2125748","article-title":"BRD4 PROTAC degrader MZ1 exerts anticancer effects in acute myeloid leukemia by targeting c-Myc and ANP32B genes","volume":"23","author":"Ma","year":"2022","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.drudis.2026.104822_b0465","doi-asserted-by":"crossref","first-page":"29742","DOI":"10.1021\/jacs.5c04918","article-title":"DNA-templated spatially controlled proteolysis targeting chimera for cyclin D1-CDK4\/6 complex protein degradation","volume":"147","author":"Zheng","year":"2025","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.drudis.2026.104822_b0470","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105447","article-title":"Discovery of KRas G12C-IN-3 and pomalidomide-based PROTACs as degraders of endogenous KRAS G12C with potent anticancer activity","volume":"117","author":"Li","year":"2021","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.drudis.2026.104822_b0475","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1021\/acs.jmedchem.2c00739","article-title":"Structure-based discovery of selective histone deacetylase 8 degraders with potent anticancer activity","volume":"66","author":"Huang","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104822_b0480","doi-asserted-by":"crossref","first-page":"10167","DOI":"10.1021\/acs.jmedchem.1c00460","article-title":"Design, synthesis, and evaluation of VHL-based EZH2 degraders to enhance therapeutic activity against lymphoma","volume":"64","author":"Tu","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104822_b0485","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113922","article-title":"Identification of a selective BRD4 PROTAC with potent antiproliferative effects in AR-positive prostate cancer based on a dual BET\/PLK1 inhibitor","volume":"227","author":"Hu","year":"2022","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.drudis.2026.104822_b0490","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202415323","article-title":"MicroRNA-triggered programmable DNA-encoded pre-PROTACs for cell-selective and controlled protein degradation","volume":"64","author":"Zhan","year":"2025","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.drudis.2026.104822_b0495","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1038\/s41401-024-01266-z","article-title":"Tumor-targeted PROTAC prodrug nanoplatform enables precise protein degradation and combination cancer therapy","volume":"45","author":"Zou","year":"2024","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.drudis.2026.104822_b0500","article-title":"Proteolysis targeting chimeras (PROTACs) based on imatinib induced degradation of BCR-ABL in K562 cells","volume":"8","author":"Li","year":"2023","journal-title":"ChemistrySelect"},{"key":"10.1016\/j.drudis.2026.104822_b0505","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.107078","article-title":"Design, synthesis, and evaluation of VHL-based EZH2 degraders for breast cancer","volume":"143","author":"Xiao","year":"2024","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.drudis.2026.104822_b0510","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41421-020-0171-1","article-title":"A PROTAC peptide induces durable \u03b2-catenin degradation and suppresses Wnt-dependent intestinal cancer","volume":"6","author":"Liao","year":"2020","journal-title":"Cell Discov"},{"key":"10.1016\/j.drudis.2026.104822_b0515","doi-asserted-by":"crossref","DOI":"10.1002\/slct.202203463","article-title":"Proteolysis targeting chimeras (PROTACs) based on promiscuous kinase inhibitor synergistically induce cancer cell apoptosis through multiple mechanisms","volume":"7","author":"Zhai","year":"2022","journal-title":"ChemistrySelect"},{"key":"10.1016\/j.drudis.2026.104822_b0520","doi-asserted-by":"crossref","first-page":"9842","DOI":"10.1021\/acs.jmedchem.3c02340","article-title":"Novel amphiphilic PROTAC with enhanced pharmacokinetic properties for ALK protein degradation","volume":"67","author":"Wang","year":"2024","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104822_b0525","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112186","article-title":"Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity","volume":"192","author":"Zhang","year":"2020","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.drudis.2026.104822_b0530","doi-asserted-by":"crossref","first-page":"17319","DOI":"10.1021\/acs.jmedchem.4c01223","article-title":"Discovery of Novel PROTAC SIRT6 degraders with potent efficacy against hepatocellular carcinoma","volume":"67","author":"Huang","year":"2024","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104822_b0535","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.114088","article-title":"Efficient targeted oncogenic KRASG12C degradation via first reversible-covalent PROTAC","volume":"230","author":"Yang","year":"2022","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.drudis.2026.104822_b0540","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.104453","article-title":"Targeted degradation of CD147 proteins in melanoma","volume":"105","author":"Zhou","year":"2020","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.drudis.2026.104822_b0545","doi-asserted-by":"crossref","first-page":"6397","DOI":"10.1021\/acs.jmedchem.3c02394","article-title":"Discovery of the first-in-class G9a\/GLP PROTAC degrader","volume":"67","author":"Velez","year":"2024","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104822_b0550","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.129041","article-title":"Sunitinib-based proteolysis targeting chimeras (PROTACs) reduced the protein levels of FLT-3 and c-KIT in leukemia cell lines","volume":"78","author":"Zhai","year":"2022","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.drudis.2026.104822_b0555","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.bcp.2019.03.023","article-title":"High-selective HDAC6 inhibitor promotes HDAC6 degradation following autophagy modulation and enhanced antitumor immunity in glioblastoma","volume":"163","author":"Liu","year":"2019","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.drudis.2026.104822_b0560","doi-asserted-by":"crossref","first-page":"17046","DOI":"10.1021\/acs.jmedchem.5c00468","article-title":"GLUTs-facilitated targeting BRD4 degradation in breast cancer through carbohydrate-conjugated PROTACs","volume":"68","author":"Gao","year":"2025","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104822_b0565","doi-asserted-by":"crossref","first-page":"18684","DOI":"10.1021\/acs.jmedchem.5c01834","article-title":"Discovery of dual BCL-xL\/BCL-w degraders by exploiting the bis(sulfonyl)benzene ring of ABT-263 as a linkage vector","volume":"68","author":"Poddar","year":"2025","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104822_b0570","doi-asserted-by":"crossref","first-page":"8208","DOI":"10.1021\/acs.jmedchem.4c02909","article-title":"Pt(IV)-PROTAC complexes with synergistic antitumor activity and enhanced membrane permeability","volume":"68","author":"Li","year":"2025","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104822_b0575","article-title":"Development of highly potent and selective oncogenic KRASG12D PROTAC degraders","volume":"15","author":"Mao","year":"2025","journal-title":"Eur J Med Chem Rep"},{"key":"10.1016\/j.drudis.2026.104822_b0580","doi-asserted-by":"crossref","first-page":"5616","DOI":"10.1021\/acs.jmedchem.4c02884","article-title":"Selective degradation of TEADs by a PROTAC molecule exhibited robust anticancer efficacy in vitro and in vivo","volume":"68","author":"Lu","year":"2025","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104822_b0585","doi-asserted-by":"crossref","first-page":"6121","DOI":"10.1007\/s11030-025-11140-7","article-title":"Discovery of the novel celastrol-based PROTACs for the treatment of non-small cell lung cancer","volume":"29","author":"Ma","year":"2025","journal-title":"Mol Divers"},{"key":"10.1016\/j.drudis.2026.104822_b0590","doi-asserted-by":"crossref","first-page":"4846","DOI":"10.1038\/s41388-025-03641-4","article-title":"A selective RPL15 PROTAC degrader enhances anti-PD-1 immunotherapy in a murine melanoma tumor model","volume":"44","author":"Takahashi","year":"2025","journal-title":"Oncogene"},{"key":"10.1016\/j.drudis.2026.104822_b0595","doi-asserted-by":"crossref","first-page":"12800","DOI":"10.1021\/acs.jmedchem.5c00679","article-title":"Discovery and optimization of potent PROTAC degraders of phosphoinositide 3-kinase with significant in vivo anticancer efficacy","volume":"68","author":"Peng","year":"2025","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104822_b0600","first-page":"134","article-title":"Utilizing the HiBiT system to identify CARM1 degraders for targeted cancer therapy","volume":"69","author":"Bacabac","year":"2026","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104822_b0605","doi-asserted-by":"crossref","first-page":"9374","DOI":"10.1038\/s41467-025-64426-7","article-title":"Targeted degradation of endogenous YAP by nanobody bioPROTAC inhibits tumor progression","volume":"16","author":"Zhou","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2026.104822_b0610","article-title":"ARV-771 acts as an inducer of cell cycle arrest and apoptosis to suppress hepatocellular carcinoma progression","volume":"13","author":"Deng","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.drudis.2026.104822_b0615","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.bioorg.2019.03.035","article-title":"Pomalidomide hybrids act as proteolysis targeting chimeras: synthesis, anticancer activity and B-Raf degradation","volume":"87","author":"Chen","year":"2019","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.drudis.2026.104822_b0620","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1016\/j.immuni.2024.04.025","article-title":"A RIPK1-specific PROTAC degrader achieves potent antitumor activity by enhancing immunogenic cell death","volume":"57","author":"Mannion","year":"2024","journal-title":"Immunity"},{"key":"10.1016\/j.drudis.2026.104822_b0625","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108316","article-title":"Identification of a novel azaspirooxindolinone-based PROTAC for selective BTK degradation and enhanced anticancer activity","volume":"157","author":"Rampeesa","year":"2025","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.drudis.2026.104822_b0630","doi-asserted-by":"crossref","first-page":"4794","DOI":"10.1038\/s41467-025-60107-7","article-title":"Linker-free PROTACs efficiently induce the degradation of oncoproteins","volume":"16","author":"Zhang","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2026.104822_b0635","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1158\/1535-7163.MCT-11-0401","article-title":"The NEDD8-activating enzyme inhibitor, MLN4924, cooperates with TRAIL to augment apoptosis through facilitating c-FLIP degradation in head and neck cancer cells","volume":"10","author":"Zhao","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.drudis.2026.104822_b0640","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1038\/s41388-020-01586-4","article-title":"TAS4464, a NEDD8-activating enzyme inhibitor, activates both intrinsic and extrinsic apoptotic pathways via c-Myc-mediated regulation in acute myeloid leukemia","volume":"40","author":"Ochiiwa","year":"2021","journal-title":"Oncogene"},{"key":"10.1016\/j.drudis.2026.104822_b0645","doi-asserted-by":"crossref","first-page":"9866","DOI":"10.1039\/D0CC03243C","article-title":"Discovery of histone deacetylase 3 (HDAC3)-specific PROTACs","volume":"56","author":"Xiao","year":"2020","journal-title":"Chem Commun (Camb)"},{"key":"10.1016\/j.drudis.2026.104822_b0650","doi-asserted-by":"crossref","DOI":"10.1002\/cpz1.611","article-title":"Targeted protein degradation: design considerations for PROTAC development","volume":"2","author":"Tran","year":"2022","journal-title":"Curr Protoc"},{"key":"10.1016\/j.drudis.2026.104822_b0655","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.753119","article-title":"ARV-825 demonstrates antitumor activity in gastric cancer via MYC-targets and G2M-checkpoint signaling pathways","volume":"11","author":"Liao","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.drudis.2026.104822_b0660","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117381","article-title":"Discovery of highly potent dual GSPT1\/BRD4 degraders with anti-AML activity","volume":"288","author":"Xu","year":"2025","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.drudis.2026.104822_b0665","unstructured":"LifeSensors Inc. PA770: PROTAC\u00ae in vitro ubiquitination assay kit. Accessed 11 August 2025. https:\/\/lifesensors.com\/product\/pa770-protac-in-vitro-ubiquitination-assay-kit."},{"key":"10.1016\/j.drudis.2026.104822_b0670","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1586\/14789450.2014.939635","article-title":"The necessity of and strategies for improving confidence in the accuracy of western blots","volume":"11","author":"Ghosh","year":"2014","journal-title":"Expert Rev Proteomics"},{"key":"10.1016\/j.drudis.2026.104822_b0675","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/978-1-0716-1186-9_29","article-title":"Technical considerations for contemporary western blot techniques","volume":"2261","author":"Oh","year":"2021","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.drudis.2026.104822_b0680","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41387-018-0030-4","article-title":"Human adipose tissue protein analyses using capillary western blot technology","volume":"8","author":"Lu","year":"2018","journal-title":"Nutr Diabetes"},{"key":"10.1016\/j.drudis.2026.104822_b0685","doi-asserted-by":"crossref","DOI":"10.1002\/cpz1.70326","article-title":"Protocols for monitoring unconventional protein secretion using luminescence and trapping approaches","volume":"6","author":"N\u00e9el","year":"2026","journal-title":"Curr Protoc"},{"key":"10.1016\/j.drudis.2026.104822_b0690","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1021\/acschembio.8b00692","article-title":"Quantitative live-cell kinetic degradation and mechanistic profiling of PROTAC mode of action","volume":"13","author":"Riching","year":"2018","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.drudis.2026.104822_b0695","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.molcel.2016.05.020","article-title":"Ubiquilins chaperone and triage mitochondrial membrane proteins for degradation","volume":"63","author":"Itakura","year":"2016","journal-title":"Mol Cell"},{"key":"10.1016\/j.drudis.2026.104822_b0700","doi-asserted-by":"crossref","first-page":"e3597","DOI":"10.21769\/BioProtoc.3597","article-title":"Dual fluorescence cytometry assay to assess cellular protein levels","volume":"10","author":"Ngo","year":"2020","journal-title":"Bio Protoc"},{"key":"10.1016\/j.drudis.2026.104822_b0705","doi-asserted-by":"crossref","first-page":"5329","DOI":"10.3390\/molecules29225329","article-title":"Effects of biguanide-PROTACs in pancreatic cancer cells","volume":"29","author":"Vatt\u00e9","year":"2024","journal-title":"Molecules"},{"key":"10.1016\/j.drudis.2026.104822_b0710","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.3390\/molecules25081948","article-title":"Design, synthesis, and biological evaluation of proteolysis targeting chimeras (PROTACs) for the dual degradation of IGF-1R and Src","volume":"25","author":"Manda","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.drudis.2026.104822_b0715","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.113150","article-title":"Discovery of a PROTAC targeting ALK with in vivo activity","volume":"212","author":"Yan","year":"2021","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.drudis.2026.104822_b0720","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.106327","article-title":"Design, synthesis, and biological evaluation of novel protopanoxadiol derivatives based PROTACs technology for the treatment of lung cancer","volume":"131","author":"Wang","year":"2023","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.drudis.2026.104822_b0725","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1007\/s11095-022-03184-3","article-title":"Susceptibility of lung carcinoma cells to nanostructured lipid carrier of ARV-825, a BRD4 degrading proteolysis targeting chimera","volume":"39","author":"Vartak","year":"2022","journal-title":"Pharm Res"},{"key":"10.1016\/j.drudis.2026.104822_b0730","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.104901","article-title":"Design and linkage optimization of ursane-thalidomide-based PROTACs and identification of their targeted-degradation properties to MDM2 protein","volume":"111","author":"Qi","year":"2021","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.drudis.2026.104822_b0735","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1021\/acs.jmedchem.1c01768","article-title":"Discovery of the first examples of threonine tyrosine kinase PROTAC degraders","volume":"65","author":"Lu","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104822_b0740","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.2217\/nnm-2020-0156","article-title":"Nanoformulation of PROteolysis TArgeting Chimera targeting \u2018undruggable\u2019 c-Myc for the treatment of pancreatic cancer","volume":"15","author":"Saraswat","year":"2020","journal-title":"Nanomedicine (Lond)"},{"key":"10.1016\/j.drudis.2026.104822_b0745","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2024.117982","article-title":"Design, synthesis and biological evaluation of novel TMPRSS2-PROTACs with florosubstituted 4-guanidino-N-phenylbenzamide derivative ligands","volume":"116","author":"Yang","year":"2024","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.drudis.2026.104822_b0750","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.3390\/cimb46030111","article-title":"Targeting CDK9 in cancer: an integrated approach of combining in silico screening with experimental validation for novel degraders","volume":"46","author":"Koirala","year":"2024","journal-title":"Curr Issues Mol Biol"},{"key":"10.1016\/j.drudis.2026.104822_b0755","doi-asserted-by":"crossref","first-page":"6566","DOI":"10.1038\/s41388-021-02041-8","article-title":"BET protein degradation triggers DR5-mediated immunogenic cell death to suppress colorectal cancer and potentiate immune checkpoint blockade","volume":"40","author":"Tong","year":"2021","journal-title":"Oncogene"},{"key":"10.1016\/j.drudis.2026.104822_b0760","doi-asserted-by":"crossref","first-page":"446","DOI":"10.3390\/biom9090446","article-title":"New thalidomide-resembling dicarboximides target ABC50 protein and show antileukemic and immunomodulatory activities","volume":"9","author":"Cie\u015blak","year":"2019","journal-title":"Biomolecules"},{"key":"10.1016\/j.drudis.2026.104822_b0765","doi-asserted-by":"crossref","first-page":"22494","DOI":"10.1002\/anie.202006725","article-title":"Hydroxamic acids immobilized on resins (HAIRs): synthesis of dual-targeting HDAC inhibitors and HDAC degraders (PROTACs)","volume":"59","author":"Sinatra","year":"2020","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.drudis.2026.104822_b0770","article-title":"Checkpoint nano-PROTACs for activatable cancer photo-immunotherapy","volume":"35","author":"Zhang","year":"2023","journal-title":"Adv Mater"},{"key":"10.1016\/j.drudis.2026.104822_b0775","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107319","article-title":"Discovery of novel co-degradation CK1\u03b1 and CDK7\/9 PROTACs with p53 activation for treating acute myeloid leukemia","volume":"147","author":"Wang","year":"2024","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.drudis.2026.104822_b0780","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.3389\/fonc.2019.01471","article-title":"Targeting BET proteins with a PROTAC molecule elicits potent anticancer activity in HCC cells","volume":"9","author":"Zhang","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.drudis.2026.104822_b0785","article-title":"Design, synthesis, and biological characterization of a potent STAT3 degrader for the treatment of gastric cancer","volume":"13","author":"Li","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.drudis.2026.104822_b0790","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.jconrel.2024.08.032","article-title":"Controlled bioorthogonal activation of Bromodomain-containing protein 4 degrader by co-delivery of PROTAC and Pd-catalyst for tumor-specific therapy","volume":"374","author":"Li","year":"2024","journal-title":"J Control Release"},{"key":"10.1016\/j.drudis.2026.104822_b0795","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.3390\/molecules27051655","article-title":"Rational design and synthesis of HSF1-PROTACs for anticancer drug development","volume":"27","author":"Sharma","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.drudis.2026.104822_b0800","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1186\/s13046-022-02483-2","article-title":"Peptide-based PROTAC degrader of FOXM1 suppresses cancer and decreases GLUT1 and PD-L1 expression","volume":"41","author":"Wang","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.drudis.2026.104822_b0805","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1080\/14756366.2022.2062338","article-title":"Design, synthesis, and molecular docking studies of novel pomalidomide-based PROTACs as potential anti-cancer agents targeting EGFRWT and EGFRT790M","volume":"37","author":"Aboelez","year":"2022","journal-title":"J Enzyme Inhib Med Chem"},{"key":"10.1016\/j.drudis.2026.104822_b0810","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202500035","article-title":"Replacing a cereblon ligand by a DDB1 and CUL4 associated factor 11 (DCAF11) recruiter converts a selective histone deacetylase 6 PROTAC into a pan-degrader","volume":"20","author":"Feller","year":"2025","journal-title":"ChemMedChem"},{"key":"10.1016\/j.drudis.2026.104822_b0815","article-title":"CDT prodrug therapy with cascade-activated PROTAC delivery platform for mutually reinforced ferroptosis and apoptosis-based therapy","volume":"36","author":"Xu","year":"2025","journal-title":"Adv Funct Mater"},{"key":"10.1016\/j.drudis.2026.104822_b0820","doi-asserted-by":"crossref","first-page":"3981","DOI":"10.1039\/D5QI00605H","article-title":"A platinated prodrug leveraging PROTAC technology for targeted protein degradation and enhanced antitumor efficacy","volume":"12","author":"Xu","year":"2025","journal-title":"Inorg Chem Front"},{"key":"10.1016\/j.drudis.2026.104822_b0825","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s11030-025-11166-x","article-title":"Design, synthesis, and biological evaluation of RIPK1-targeting PROTACs","volume":"30","author":"Zhang","year":"2026","journal-title":"Mol Divers"},{"key":"10.1016\/j.drudis.2026.104822_b0830","doi-asserted-by":"crossref","DOI":"10.1002\/slct.202405728","article-title":"Design, synthesis, and anticancer activity evaluation of the new SHP2 degraders","volume":"10","author":"Zhao","year":"2025","journal-title":"ChemistrySelect"},{"key":"10.1016\/j.drudis.2026.104822_b0835","doi-asserted-by":"crossref","DOI":"10.1080\/14756366.2025.2468355","article-title":"Design and synthesis of novel HDAC6 inhibitor dimer as HDAC6 degrader for cancer treatment by palladium catalysed dimerisation","volume":"40","author":"Lin","year":"2025","journal-title":"J Enzyme Inhib Med Chem"},{"key":"10.1016\/j.drudis.2026.104822_b0840","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpet.2025.103772","article-title":"Targeting of Brahma-related gene-1 (BRG1) overcomes paclitaxel-induced multidrug resistance caused by overexpression of the subset of ATP-binding cassette (ABC) transporters","volume":"392","author":"Gronkowska","year":"2025","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.drudis.2026.104822_b0845","doi-asserted-by":"crossref","first-page":"4014","DOI":"10.3390\/molecules28104014","article-title":"PROTACs: emerging targeted protein degradation approaches for advanced druggable strategies","volume":"28","author":"Sincere","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.drudis.2026.104822_b0850","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1042\/BCJ20243018","article-title":"Methods to accelerate PROTAC drug discovery","volume":"482","author":"Osman","year":"2025","journal-title":"Biochem J"},{"key":"10.1016\/j.drudis.2026.104822_b0855","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.3390\/pharmaceutics16081070","article-title":"Unlocking the potential of camel milk-derived exosomes as novel delivery systems: enhanced bioavailability of ARV-825 PROTAC for cancer therapy","volume":"16","author":"Nathani","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.drudis.2026.104822_b0860","doi-asserted-by":"crossref","first-page":"220","DOI":"10.3390\/ijms26010220","article-title":"An overview of the current state of cell viability assessment methods using OECD classification","volume":"26","author":"Madorran","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2026.104822_b0865","doi-asserted-by":"crossref","DOI":"10.1177\/1179670717691251","article-title":"In vitro cell death determination for drug discovery: a landscape review of real issues","volume":"10","author":"M\u00e9ry","year":"2017","journal-title":"J Cell Death"},{"key":"10.1016\/j.drudis.2026.104822_b0870","doi-asserted-by":"crossref","first-page":"12036","DOI":"10.1021\/acsomega.9b01142","article-title":"Comparison of cytotoxicity evaluation of anticancer drugs between real-time cell analysis and CCK-8 method","volume":"4","author":"Cai","year":"2019","journal-title":"ACS Omega"},{"key":"10.1016\/j.drudis.2026.104822_b0875","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1038\/s41419-019-2022-2","article-title":"PROTAC induced-BET protein degradation exhibits potent anti-osteosarcoma activity by triggering apoptosis","volume":"10","author":"Shi","year":"2019","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.drudis.2026.104822_b0880","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1186\/s12885-025-14361-z","article-title":"Mdm2 targeting via PROteolysis TArgeting Chimeras (PROTAC) is efficient in p53 wildtype, p53-mutated, and abemaciclib-resistant estrogen receptor-positive cell lines and superior to mdm2 inhibition","volume":"25","author":"Goerg","year":"2025","journal-title":"BMC Cancer"},{"key":"10.1016\/j.drudis.2026.104822_b0885","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1007\/s13402-025-01111-3","article-title":"A novel \u03b2-carboline alkaloid derivative targeting MDM2-p53 pathway suppresses colorectal cancer progression","volume":"48","author":"Zeng","year":"2025","journal-title":"Cell Oncol (Dordr)"},{"key":"10.1016\/j.drudis.2026.104822_b0890","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.cell.2015.08.068","article-title":"Preclinical mouse cancer models: a maze of opportunities and challenges","volume":"163","author":"Day","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2026.104822_b0895","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1177\/2472555220979584","article-title":"Target validation using PROTACs: applying the four pillars framework","volume":"26","author":"Nowak","year":"2021","journal-title":"SLAS Discov"},{"key":"10.1016\/j.drudis.2026.104822_b0900","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1177\/0300985813505879","article-title":"When tissue antigens and antibodies get along: revisiting the technical aspects of immunohistochemistry\u2014the red, brown, and blue technique","volume":"51","author":"Ramos-Vara","year":"2014","journal-title":"Vet Pathol"},{"key":"10.1016\/j.drudis.2026.104822_b0905","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s11095-019-2745-x","article-title":"Intraperitoneal route of drug administration: should it be used in experimental animal studies?","volume":"37","author":"Al Shoyaib","year":"2019","journal-title":"Pharm Res"},{"key":"10.1016\/j.drudis.2026.104822_b0910","doi-asserted-by":"crossref","first-page":"5330","DOI":"10.1039\/D1CS00762A","article-title":"Proteolysis-targeting chimera (PROTAC) delivery system: advancing protein degraders towards clinical translation","volume":"51","author":"Chen","year":"2022","journal-title":"Chem Soc Rev"},{"key":"10.1016\/j.drudis.2026.104822_b0915","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/s43856-024-00505-y","article-title":"Tissue distribution and retention drives efficacy of rapidly clearing VHL-based PROTACs","volume":"4","author":"Zhang","year":"2024","journal-title":"Commun Med (Lond)"},{"key":"10.1016\/j.drudis.2026.104822_b0920","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2025.104311","article-title":"PK\/PD modeling of targeted protein degraders: charting new waters and navigating the shallows","volume":"30","author":"Haid","year":"2025","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.drudis.2026.104822_b0925","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2024.116348","article-title":"Development and validation of LC-MS\/MS methods for the pharmacokinetic assessment of the PROTACs bavdeglutamide (ARV-110) and vepdegestrant (ARV-471)","volume":"249","author":"Niessen","year":"2024","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.drudis.2026.104822_b0930","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1021\/acscentsci.3c00395","article-title":"Proximity-based modalities for biology and medicine","volume":"9","author":"Liu","year":"2023","journal-title":"ACS Cent Sci"},{"key":"10.1016\/j.drudis.2026.104822_b0935","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1021\/acsmedchemlett.2c00124","article-title":"Direct-to-biology accelerates PROTAC synthesis and the evaluation of linker effects on permeability and degradation","volume":"13","author":"Hendrick","year":"2022","journal-title":"ACS Med Chem Lett"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644626002278?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644626002278?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T23:42:30Z","timestamp":1792712550000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644626002278"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":187,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S1359644626002278"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104822","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Overview of screening assays used to evaluate PROTACs for cancer treatment","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104822","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104822"}}